menu
    • menu
    [{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0.11,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Flagship Pioneering \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Flagship Pioneering \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Novo Nordisk"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Evelo Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"EDP1815","moa":"TLR2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Flagship Pioneering","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"8","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"Tamibarotene","moa":"RAR alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Flagship Pioneering","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"10","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Senda Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Series C Financing","leadProduct":"SendRNA Therapeutic","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Flagship Pioneering","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"4","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Cellarity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0.27000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Flagship Pioneering \/ Pioneering Medicines","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Pioneering Medicines"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Metaphore Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Empress Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Evelo Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"EDP2939","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Flagship Pioneering","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"8","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Alltrna","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Series B Financing","leadProduct":"tRNA Medicine","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Flagship Pioneering","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"ProFound Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Abiologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Synteins-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Flagship Pioneering","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Flagship Pioneering \/ Flagship Pioneering","highestDevelopmentStatusID":"14","companyTruncated":"Flagship Pioneering \/ Flagship Pioneering"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Flagship Pioneering","amount2":7.2000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Flagship Pioneering \/ GSK","highestDevelopmentStatusID":"14","companyTruncated":"Flagship Pioneering \/ GSK"}]

    Find Clinical Drug Pipeline Developments & Deals by Flagship Pioneering

    Menu

    Flagship Pioneering

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : GSK

                            Deal Size : $7,200.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GSK becomes Flagship's latest partner in $7B biobucks respiratory, immunology pact

                            Details : The Flagship collaborates with GSK to discover and develop a portfolio of future transformational medicines and vaccines for the treatment of respiratory and immunology diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : $150.0 million

                            July 29, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : GSK

                            Deal Size : $7,200.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Synteins-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Abiologics

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Flagship’s Abiologics sets sail with $50M for synthetic protein R&D

                            Details : The proceeds will advance company's platform and develop a diverse pipeline of medicines, Synteins, with an initial focus on oncology and immunology indications.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 23, 2024

                            Lead Product(s) : Synteins-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Abiologics

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery Platform

                            Recipient : ProFound Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Flagship Pioneering and ProFound Collaborate on First-in-Class Therapeutics for Obesity

                            Details : ProFound will deploy its proprietary ProFoundry Platform in collaboration with Pioneering Medicines' expertise to discover novel proteins and evaluate their therapeutic relevance for obesity.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 12, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery Platform

                            Recipient : ProFound Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : tRNA Medicine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Recipient : Alltrna

                            Deal Size : $109.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease

                            Details : The financing will be used to advance the company's platform and first drug candidates towards the clinic for a first indication in Stop Codon Disease.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 09, 2023

                            Lead Product(s) : tRNA Medicine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Recipient : Alltrna

                            Deal Size : $109.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EDP2939

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : Evelo Biosciences

                            Deal Size : $25.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Evelo Biosciences Closes $25.5 Million Private Placement

                            Details : The company intends to use the net proceeds to fund the completion of the Company’s ongoing Phase 2a trial of EDP2939, an investigational orally delivered and gut-restricted bacterial extracellular vesicle being developed for the treatment of moderate ...

                            Brand Name : EDP2939

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 12, 2023

                            Lead Product(s) : EDP2939

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : Evelo Biosciences

                            Deal Size : $25.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Recipient : Empress Therapeutics

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Gene...

                            Details : The net proceeds will be used to support the development of Empress's proprietary Chemilogics™ product platform which creates potential small molecule medicines and the company's initial pipeline of drug candidates.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 21, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Recipient : Empress Therapeutics

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Recipient : Metaphore Biotechnologies

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry

                            Details : The proceeds will advance Metaphore's MIMiC drug discovery platform and build its pipeline for autoimmune, metabolic or oncology indications. The MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules for t...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 16, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Recipient : Metaphore Biotechnologies

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Recipient : Charles River Laboratories International

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of C...

                            Details : Under the agreement, Logica, an offering from Charles River and Valo Health will be deployed by Pioneering Medicines across a portfolio of targets with the aim of creating optimized small molecules that lead to novel therapies for unmet medical needs.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 16, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Recipient : Charles River Laboratories International

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Cellarity

                            Deal Size : $274.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Cellarity Announces Close of $121 Million Series C Financing

                            Details : The proceeds of the financing will be used to grow Cellarity’s talent base, strengthen its platform, and advance its pipeline toward the clinic with the development of compounds that have been validated in vitro and in vivo, including in higher species...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 04, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Cellarity

                            Deal Size : $274.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Flagship Pioneering

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SendRNA Therapeutic

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Senda Biosciences

                            Deal Size : $123.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Senda Biosciences Announces Close of $123 Million Series C Financing

                            Details : The proceeds of the financing will be used to drive further development of Senda’s proprietary programmable medicines platform and advance its first programs into clinical testing. Senda is developing a new class of SendRNA™ medicines.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 16, 2022

                            Lead Product(s) : SendRNA Therapeutic

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Senda Biosciences

                            Deal Size : $123.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth